Seek and treat: HIV update 2011

Cleveland Clinic Journal of Medicine

Volumn 78, Issue 2, 2011, Pages 95-100

  Taege, Alan ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PUBLIC HEALTH SERVICE; STATISTICS; TIME; UNITED STATES;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HIV INFECTIONS; HIV-1; HUMANS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 79751489294     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78gr.10003     Document Type: Article

References (28)

1. Van Sighem A, Gras L, Reiss P, Brinkman K, de Wolf F, and ATHENA Natl Observational Cohort Study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. Presented at the 17th Conference on Ret-roviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 526.
2. World Health Organization. Principles and Practice of Screening for Disease. WHO Public Health Paper, 1968.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). Global Facts & Figures 09. http://data.unaids.org/pub/FactSheet/2009/20091124_FS_global_en.pdf. Accessed 1/4/2011.
4. World Health Organization. Epidemiological Fact Sheet on HIV and AIDS. Core data on epidemiology and response. United States of America. 2008 Update. http://apps.who.int/globalatlas/predefne-dReports/EFS2008/full/EFS2008_US.pdf. Accessed 1/4/2011.
5. US Centers for Disease Control and Prevention. HIV Surveillance Report, 2008; vol. 20. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Published June 2010. Accessed 8/7/2010.
6. Hall HI, Song R, Rhodes P, et al; HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
7. Marks G, Crepaz N, Janssen RS. Estimated sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006; 20:1447-1450.
8. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultsandAdolescentGL.pdf. Accessed 1/4/2011.
9. Palella F, Armon C, Buchacz, et al; the HOPS Investigators. CD4 at HAART initiation predicts long term CD4 responses and mortality from AIDS and non-AIDS causes in the HIV Outpatient Study (HOPS). Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 983.
10. Althoff K, Gange S, Klein M, et al; the North American-AIDS Cohort Collaboration on Res and Design. Late presentation for HIV care in the United States and Canada. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 982.
11. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
12. Simard E, Pfeiffer R, Engels E. Cancer incidence and cancer-attributable mortality among persons with AIDS in the United States. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 27.
13. Silverberg M, Xu L, Chao C, et al. Immunodeficiency, HIV RNA levels, and risk of non-AIDS-defining cancers. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 28.
14. DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretrovi-ral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
15. Ho J, Deeks S, Hecht F, et al. Earlier initiation of antiretroviral therapy in HIV-infected individuals is associated with reduced arterial stiffness. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 707.
16. Dao C, Young B, Buchacz K, Baker R, Brooks J, and the HIV Outpatient Study Investigators. Higher and increasing rates of fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared to the general US population 1994 to 2008. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 128.
17. Ellis R, Heaton R, Letendre S, et al; the CHARTER Group. Higher CD4 nadir is associated with reduced rates of HIV-associated neurocog-nitive disorders in the CHARTER study: potential implications for early treatment initiation. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 429.
18. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-264.
19. Castel A, Samala R, Griffn A, et al. Monitoring the impact of expanded HIV testing in the District of Columbia using population-based HIV/AIDS surveillance data. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 34.
20. Montaner J, Wood E, Kerr T, et al. Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly mong injection drug users in British Columbia, Canada. Presented at the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 88LB.
21. Donnell D, Kiarie J, Thomas K, et al. ART and risk of heterosexual HIV-1 transmissin in HIV-1 serodiscordant African couples: a multinational prospective study. Presented at the 17th Conference on Retro-viruses and Opportunistic Infections; San Francisco, CA, February 16-19, 2010. Abstract 136.
22. Centers for Disease Control and Prevention. Late versus early testing of HIV-16 sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep 2003; Jun 27;52(25):581-586.
23. Wilson SR, Mitchell C, Bradbury DR, Chavez J. Testing for HIV: current practies in the academic ED. Am J Emerg Med 1999; 17:346-356.
24. Fincher-Mergi M, Cartone KJ, Mischler J, Pasieka P, Lerner EB, Billittier AJ 4th. Assessment of emergency department heatlh care professionals' behaviors regaridng HIV testing and referral for patients with STDs. AIDS Patient Care STDs 2002; 16:549-553.
25. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med 2005; 352:586-595.
26. Sanders GD, Gayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352:570-585.
27. Simpson WM, Johnstone FD, Goldberg DJ, Gormley SM, Hart GJ. Antenatal HIV testing: assessment of a routine voluntary approach. BMJ 1999; 318:1660-1661.
28. Branson BM, Handsfeld HH, Lampe MA, et al; Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55(RR-14):1-17.